TIDMAGY

RNS Number : 3632P

Allergy Therapeutics PLC

05 June 2015

5 June 2015

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Acquisition of Alerpharma S.A.

Building towards a leading immunotherapy business in Spain

Allergy Therapeutics, the fully integrated specialty pharmaceutical company, today announces the acquisition of the entire issued share capital of Alerpharma, S.A. ("Alerpharma"), a privately owned company based in Spain for an initial consideration of EUR3.8 million (the "Acquisition"). Alerpharma wholly owns the Spanish-based allergy immunotherapy company Instituto de Immunologia y Alergia, S.A.U. ("Inmunal"), a spin-out from a world-leading biopharmaceutical company, Zeltia S.A. Group.

Inmunal is Alerpharma's principal operating subsidiary, and is highly regarded with well-established product lines in immunotherapy vaccines, bacteriological vaccines and diagnostics. Inmunal brings a newly-built state-of-the-art 2,200 sq m manufacturing facility in the Alcala de Henares Technological Park, Madrid, and a broad product range, including a specialised franchise on an olive vaccine, which is one of the most important allergens in southern Europe. The revenue producing product portfolio and the geographical presence of Inmunal complement Allergy Therapeutics' Spanish subsidiary, making the acquisition highly synergistic. The Acquisition also creates one of the leading immunotherapy companies in the Spanish market, estimated to be third largest in Europe with estimated annual sales of EUR72 million for 2014.

Alerpharma recorded unaudited turnover and pre-tax profits of approximately EUR4.5 million and EUR146,000 respectively in the financial year ended 31 December 2014, and its unaudited net assets as at 31 December 2014 were approximately EUR2.6 million. The Board expects the Acquisition to be immediately earnings enhancing.

The initial consideration for the Acquisition of EUR3.8 million was paid to the vendor (the "Vendor") in cash at completion, funded by the Company's operational cash flows. The total consideration includes a potential earn-out payment based on certain 2016 sales performance criteria, payable to the Vendor in 2017. The earn-out payment is estimated to be up to approximately EUR2 million, based on Alerpharma's forecast sales figures, funded by associated cash flows.

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said:

"In addition to progressing with our US opportunity, building a strong business platform in Europe has been a top priority for our management team. Spain represents a very logical target market for Allergy Therapeutics because it is our second largest market after Germany, but it is where we currently have our lowest comparative market share. The Acquisition, therefore, provides us with the opportunity to grow our business in this important market. The combination of our Spanish subsidiary and Inmunal will provide us with significant cross selling opportunities and cost synergies, which will enhance our market share and increase our critical mass, enabling us to become one of the leading allergy immunotherapy companies in the Spanish market."

-Ends-

For further information

 
 Allergy Therapeutics                          +44 (0) 1903 845 820 
 Manuel Llobet, Chief Executive Officer 
  Ian Postlethwaite, Finance Director 
 
 Panmure Gordon 
 Freddy Crossley / Peter Steel / Duncan 
  Monteith 
  Corporate Finance                            +44 (0) 20 7886 2500 
 Tom Salvesen 
  Corporate Broking 
 
 FTI Consulting                                +44 (0) 20 3727 1000 
 Simon Conway / Mo Noonan / Victoria Foster 
  Mitchell

Notes to editors

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. It recently raised GBP20 million in April 2015 via a placing to continue with its clinical trials in the US.

About Alerpharma and Inmunal

Alerpharma, S.A., a privately owned company based in Spain, acquired Instituto de Immunologia y Alergia, S.A.U. (Inmunal), the Spanish-based allergy immunotherapy company in 2002. Inmunal was originally founded in 1989 by world-leading biopharmaceutical company, Zeltia S.A. Group. Alerpharma has 39 employees, with its headquarters in Parque Cientifico Tecnologico Alcala de Henares and a recently built a state-of-the-art 2,200 sq m manufacturing facility in the Alcala de Henares Technological Park, Madrid. In the financial year ended 31 December 2014, Alerpharma recorded sales of EUR4.5 million.

Inmunal, Alerpharma's principal operating subsidiary, focuses on immunotherapy vaccines, bacteriological vaccines and diagnostics, including a specialised franchise on an olive vaccine, one of the most important allergens in southern Europe. The Spanish immunotherapy market is estimated to be third largest in Europe with estimated annual sales of EUR72 million for 2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

ACQFAMLTMBAMMRA

Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Allergy Therapeutics Charts.
Allergy Therapeutics (LSE:AGY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Allergy Therapeutics Charts.